Latest:
Dr Tan on the Management of ADC-Related Toxicities in Breast Cancer
Antoinette Tan, MD, MHS, discusses the safety profiles of ADCs and ADC selection considerations for breast cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Hira Mian, MD
Hira Mian, MD, MSc, FRCPC is an Associate Professor in the Department of Oncology at McMaster University.
Latest:
Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC
Hira Mian, MD, MSc, discusses why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristic for patients with multiple myeloma.
Megan Hollasch
Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication
Latest:
Combinations Targeting PI3K/AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer
Combinations targeting PI3K/AKT/mTOR and MAPK/ERK pathways are under investigation to improve outcomes in patients with endometrial cancer.
Marc S. Raab, MD
Marc S. Raab is a physician-scientist and Professor of Medicine at the Heidelberg University Medical Center (HUMC).
Latest:
Dr Raab on Continued Investigation of Teclistamab Plus Daratumumab-Based Induction in Myeloma
Marc S. Raab, MD, discusses future avenues for the investigation of teclistamab plus daratumumab-based induction regimens in newly diagnosed multiple myeloma.
Genmab and AbbVie Sponsored Content; OncLive Article with Tahi Ahmadi and Asud Khaliq
Latest:
Treatment Option for Adult Patients with 3L+ Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Many people living with diffuse large B-cell lymphoma (DLBCL) continue to experience significant treatment challenges. Genmab and AbbVie discuss the current DLBCL treatment landscape and an effort as part of a collaboration between the two companies for people diagnosed with relapsed or refractory DLBCL.
Thor R. Halfdanarson, MD
Latest:
Integrating Cabozantinib Into the NET Treatment Landscape
Panelists discuss cabozantinib’s role in the neuroendocrine tumor treatment landscape, emphasizing its utility as a third-line option post somatostatin analogues and systemic therapy, while highlighting its efficacy in heavily pretreated patients, the importance of careful sequencing—especially relative to PRRT—and considerations for ideal patient selection, including those with grade 3 well-differentiated tumors.
Branden Moriarity, PhD
Branden Moriarity, PhD, is an associate professor in the Division of Pediatric Hematology/Oncology, co-director of the Center for Genome Engineering and the Genome Engineering Shared Resource (GESR), and a member of the Center for Genome Engineering at the University of Minnesota in Minneapolis, where he is also a faculty member in the Department of Pediatrics; the Microbiology, Immunology and Cancer Biology (MICaB) PhD Graduate Program; the PhD Program in Molecular, Cellular, Developmental Biology and Genetics; the Cellular and Molecular Biology (CMB) Graduate Program, and the Masters Program in Stem Cell Biology. He is also a member of the Stem Cell Institute at the Masonic Cancer Center.
Latest:
CRISPR-Edited CISH Knockout TIL Therapy Paves Novel Treatment Paths in CRC: With Branden Moriarity, PhD; and Beau Webber, PhD
Drs Moriarity and Webber discuss a study evaluating neoantigen-reactive CISH knockout TIL therapy in patients with metastatic gastrointestinal cancers.
Domenica Lorusso, MD, PhD
Latest:
Dr Lorusso on the Rationale for Investigating Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
Domenica Lorusso, MD, PhD, details the rationale for the ROSELLA trial, evaluating relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.
Indiana University School of Medicine
Latest:
$3.3 Million Grant to IU Researchers Aims to Increase Colorectal Cancer Screening in Rural Indiana
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are addressing the low colorectal cancer screening rates in rural Indiana communities with a five-year, $3.3 million grant from the National Cancer Institute.
Angela Jain, MD
Angela Jain, MD, is an associate professor, Department of Hematology/Oncology; interim chief of the Division of Breast Medical Oncology; and chief of the Division of Gynecologic Medical Oncology, of Fox Chase Cancer Center.
Latest:
Dr Jain on Existing Challenges Within the TNBC Treatment Paradigm
Angela Jain, MD, details ongoing challenges with identifying optimal treatments for patients with triple-negative breast cancer.